Pipeline

Adamed Discovery is the innovation engine of the Adamed Group, focused on advancing first-in-class therapeutics in oncology and CNS through deep biological insight and translational expertise.

Our lead program, ONCO51, is a TRAIL-derived fusion protein with
a dual mechanism of action: inducing cancer cell apoptosis and inhibiting
prosurvival signaling. It has shown superior in vivo efficacy across 30+ tumor
models and entered Phase I in Q3 2025.

Our diversified pipeline also includes:

SHIELD Suppression of Host Immune Evasion through Ligand-directed Designs,
INHAPRO in lung cancers,
Exploratory programs across oncology, CNS, and metabolism.

Two women in lab coats collaborate on scientific equipment in a laboratory setting.

Key Highlights

Currently, we have 5 active projects in progress, with plans to initiate 3 additional projects in 2026. Our capacity allows us to manage up to 10 projects in the early development phase, 3 projects in in vitro/ in vivo studies and 2 projects at the IND stage.

We are equipped with a mini bioreactor system, single-use and glass vessels, for process development. Our infrastructure supports scale-up processes up to 50 liters for mammalian cell cultures and up to 100 liters for bacterial cultures, enabling the development of scalable manufacturing processes.

With state-of-the-art facilities, a scalable manufacturing processes and access to the most modern cellular and molecular biology tools, we can ensure flexibility and robustness across diverse applications.

TRAIL–DR5 in Oncology

ONCO51: A TRAIL–VEGF Fusion Protein
with Dual Antitumor Activity

Combining Apoptosis Induction
and Prosurvival Signaling Inhibition

ONCO51 is a fully-owned, next-generation biologic molecule developed
by Adamed Discovery, designed to target two critical hallmarks: apoptosis induction and prosurvival signaling inhibition. This fusion protein
combines TRAIL (TNF-related apoptosis-inducing ligand) with a VEGF-derived peptide, enabling dual antitumor activity in a single molecule.
This approach is designed to overcome limitations of first-generation
TRAIL therapies, such as poor pharmacokinetics, TRAIL resistance,
and lack of efficient clustering of death receptors.

Project co-financed by the Medical Research Agency: “The initiative covers a Phase I (Ia/Ib) clinical trial of a fusion protein with a dual anticancer mechanism (contract no. 2022/ABM/05/000006-00)

To learn more or discuss partnership opportunities, please CONTACT US

Adamed Discovery welcomes inquiries from clinical, scientific, and industry stakeholders.

01/04
Mechanism of Action

ONCO51 exerts its therapeutic effects through a dual mechanism:

TRAIL mediated activation of DR4/DR5 death receptors, selectively
inducing apoptosis in tumor cells without affecting healthy tissues
VEGF receptor interaction

02/04
Key Advantages

Potent in vivo efficacy demonstrated across more than 30 xenograft models, including rhTRAIL-resistant tumors, achieving deep and durable regressions and showing broad potential in high-unmet-need GI cancers
Improved pharmacokinetic profile over earlier TRAIL-based agents, resulting in more durable systemic exposure
Safety profile demonstrated in 28-day GLP toxicology studies
Synergistic antitumor activity through concurrent induction of apoptosis and inhibition of prosurvival signaling
Reduced risk of resistance, due to multi-target action on cancer cell survival and support systems

03/04
Clinical Development

ONCO51 has advanced to clinical evaluation, and patient recruitment for the Phase I first-in-human trial is currently in progress.

The study will assess:

Safety, tolerability, and dose-limiting toxicities
Pharmacokinetics and preliminary signs of antitumor activity
Dose expansion in gastrointestinal tract malignancies (selected solid tumors)

Initial sites will be located in Poland, with plans to enroll patients across multiple clinical centers.

04/04
Partnering Opportunity

ONCO51 represents a de-risked, Phase I–ongoing asset with broad
potential in solid tumor indications. Its dual-action design provides
a strong rationale for combination with targeted and chemotherapy
agents. The program is open for co-development or out-licensing
discussions with strategic partners.

To learn more or discuss partnership opportunities, please CONTACT US

We welcome collaboration on this next-generation class of targeted immunomodulators.

01/03
Mechanism of Action

The SHIELD fusion constructs are engineered to simultaneously:

compromise tumor cell viability by targeting essential survival pathways,
relieve immune suppression,
enhance immune cell activation,
rebalance cytokine-driven communication,
reshape the tumor microenvironment to favor anti-tumor responses.

This synergistic activity allows for a multi-pronged therapeutic approach:

In oncology, these constructs aim to convert immune-excluded (“cold”) tumors into inflamed (“hot”) microenvironments that are more responsive to treatment
In CNS disorders, controlled immune modulation has the potential to correct neuroinflammatory imbalances implicated in diseases such as epilepsy or depression.

02/03
Therapeutic Applications

Oncology

Compromise tumor cell viability by targeting essential survival pathways
Enhances tumor immune infiltration and reduces local immune suppression
Potentially effective in tumors resistant to checkpoint inhibitors or TRAIL monotherapies

Neuroinflammation

Regulates pathologic immune responses in the brain without broadly suppressing immunity
Supports neuronal survival by modulating inflammatory cytokines and microglial activation
May offer disease-modifying effects in conditions where inflammation contributes to neuronal dysfunction

03/03
Development Status

SHIELD fusion constructs are currently in the discovery phase, with exploratory in vitro and in vivo studies indicating:

Intended dual-mechanism approach, integrating essential survival pathways with immunostimulatory strategies
Preliminary discovery insights indicating potential to influence disease biology in diverse settings
Rational design focused on achieving controlled cytokine activity and a favorable safety profile

The program is positioned for co-development opportunities and future clinical translation.

01/03
Mechanistic Innovation: Dual Pathway Modulation

SORAAD is based on a multimodal ligand designed to engage two complementary pathways known to play key roles in mood regulation and neural circuit recovery. The combination of fast-acting and sustained modulatory effects has the potential to deliver efficacy comparable to that of rapid-acting agents, while avoiding their limitations — including invasiveness, safety concerns, and abuse potential.

While the exact biological targets remain undisclosed, the compound is engineered to:

Interrupt maladaptive neuroplasticity and excitatory overactivation
Enhance monoaminergic transmission associated with mood stabilisation
Achieve synergy through concurrent

This approach offers the potential for rapid, robust, and sustained antidepressant effects with a simplified oral dosing regimen.

02/03
Program Status

SORAAD is currently in the lead finding stage, with early hits under optimisation. The program focuses on drug-like small molecules, supported by in silico modelling and in vitro pharmacology.

03/03
Our Strengths in CNS Innovation

SORAAD builds on Adamed Discovery’s experience in CNS drug development, including programs based on multimodal ligands and complex target pharmacology.

Track record in CNS drug discovery, including novel scaffolds and mechanisms
Skilled, multidisciplinary R&D team with deep expertise in mood disorders
Access to broad platforms, including in silico, in vitro, and in vivo models
Strong academic collaboration network, supporting target and biomarker validation
Mechanistic synergy of dual-action compounds, integrated early in discovery

SORAAD is positioned to address a growing demand for fast-acting, scalable antidepressant therapies with a differentiated clinical profile.

CONTACT US to learn more about partnering or collaboration opportunities.

Pipeline

Key Highlights

TRAIL–DR5 in Oncology

SHIELD fusion constructs

DEFENDER

SORAAD

INHAPRO

SHIELD fusion
constructs